Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Dupixent becomes the first-ever targeted therapy ... It has been cleared for adults with uncontrolled COPD with raised blood eosinophils, a biomarker for type 2 inflammation seen in around a ...

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis ... moderate-to-severe atopic dermatitis in adults who can't control symptoms using topical ...

This is how biologic treatments can help. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults, ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...